Repare Therapeutics

Repare Therapeutics is a biotechnology company specializing in synthetic lethality-based precision oncology. Founded in 2016 by leading academics, the company uses its proprietary genome-wide, CRISPR-enabled SNIPRx® platform to discover and develop targeted cancer therapies. Repare Therapeutics focuses on therapies that target genomic instability and DNA damage repair, aiming to address cancers with high unmet medical needs and genetically-defined patient populations.

The company’s development pipeline includes several promising candidates: Camonsertib, a potential best-in-class oral small molecule inhibitor of ATR; Lunresertib, the first PKMYT1 inhibitor to enter clinical trials; RP-1664, a highly selective small molecule inhibitor of Polo-like kinase 4 (PLK4); and RP-3467, a small molecule inhibitor of polymerase theta (Polθ). Repare Therapeutics has a collaboration agreement with Roche for the development and commercialization of Camonsertib.

Repare Therapeutics conducts clinical trials in the U.S. and other countries and has offices and lab space in Cambridge, MA, and Montreal, Quebec. The company uses a synthetic lethality approach to identify novel targets and develop precision oncology therapeutics, leveraging its SNIPRx platform for novel target identification and differentiated patient selection insights. The company has a robust collection of clinical trials actively recruiting patients and continues to develop a portfolio of product candidates based on targets identified using the SNIPRx platform.